2 results
Approved WMORecruiting
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.
Approved WMOCompleted
The purpose of this study is to determine the sustained benefit on safety and efficacy of AMG 334 compared to oral prophylactics in episodic migraine patients who have previously failed 1 to 2 prophylactic migraine treatments and therefore have a…